Ahmad Al-Mubaslat, MD
Endocrinology, Diabetes & Metabolism · Saint Joseph, MONPI 1255328738
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,411 of the $35,124 with a category attached, or 89.4%. Novo Nordisk accounts for 81.8% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $23,307, more than ten times the $494 reported in 2019.
Across 86 payments — averaging $408.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$29K
- Lilly USA, LLC$5K
- AstraZeneca$236
- Sanofi$185
- Sanofi-aventis U.S. LLC$147
- Amgen$116
- plus $625 from 11 others
What the payments were for
- Speaking & faculty fees$31,41189%
- Travel & lodging$1,1983%
- Food & beverage$2,4567%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $28,721 |
| Lilly USA, LLC | 9 | $5,095 |
| AstraZeneca | 3 | $236 |
| Sanofi | 1 | $185 |
| Sanofi-aventis U.S. LLC | 2 | $147 |
| Amgen(2 entities) | 3 | $116 |
| Ascensia Diabetes Care US Inc. | 5 | $103 |
| Mannkind Corporation | 3 | $95 |
| Insulet Corporation | 5 | $92 |
| Abbott | 5 | $92 |
| Medtronic(2 entities) | 5 | $72 |
| Dexcom, Inc. | 3 | $51 |
| Radius Health, Inc. | 1 | $50 |
| AbbVie | 2 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,124 in reported general payments places this provider in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 51 | $130,230 |
| OzempicSemaglutide | 48 | $92,666 |
| JardianceEmpagliflozin | 57 | $68,398 |
| FarxigaDapagliflozin Propanediol | 36 | $38,464 |
| MounjaroTirzepatide | 24 | $25,077 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $20,952 |
| JanuviaSitagliptin Phosphate | 13 | $15,090 |
| TrulicityDulaglutide | 11 | $13,060 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $8,586 |
| Humalog Kwikpen U-100Insulin Lispro | 33 | $7,699 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $7,619 |
| Novolog FlexpenInsulin Aspart | 27 | $7,290 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $6,944 |
| Repatha SyringeEvolocumab | 12 | $5,521 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $3,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $28,721 | $92,66648 claims |
| AstraZenecaFarxiga | $236 | $38,46436 claims |
| Lilly USA, LLCMounjaro, Trulicity | $5,095 | $38,13735 claims |
| AbbVieSynthroid | $26 | $1,17411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Joseph
- Junping YangSaint Joseph$46K
- Sherry ZhouSaint Joseph$16K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.